5 / 12
Page 43
Notes:
allied
academies
J Gastroenterol Dig Dis 2017 | Volume 2, Issue 3
World Gastroenterological &
Gastroenterology and Endoscopy
October 30-31, 2017 | Toronto, Canada
World Congress on
The association of gut microbiome with diabetes mellitus type 2
Michael Doulberis
1
, Georgios Kotronis
2
, Dimitra Gialamprinou
3
, Jannis Kountouras
3
and
Panagiotis Katsinelos
3
1
Bürgerspital Hospital, Switzerland
2
Agios Pavlos Hospital, Greece
3
Aristotle University of Thessaloniki, Greece
D
iabetes mellitus type 2 (T2DM), a component of
metabolic syndrome, represents a growing public health
burden across the world and is a leading cause of death.
There is a further aggravation in the western industrialized
world, thereby taking epidemical characteristics. The
emerging and hot theme of gut microbiota, with evidence-
based results mainly stemming from animal studies, seems
to be applicable on diabetes mellitus regulation; there
is a pathogenic association between gut microbiota and
diabetes. The total amount of microbial genomes in the gut
surpasses the size of the human genome, having around
500-fold more genes that significantly complement our
coding potential. Several beneficial effects are attributed
to gut microbiota and their genes, such as the breakdown
of indigestible dietary fibers to short-chain fatty acids,
biosynthesis of amino acids and vitamins and production of
neurotransmitters and hormones. It has been postulated,
that the selective modification of the gut microflora with
the addition of certain probiotics and symbiotics, might
ameliorate metabolic dysfunction, thereby preventing
the onset of diabetes on high-risk individuals. The cutting-
edge and challenging application of gut microbiota in the
development of preventive as well as treatment stragegies
for T2DM and hyperglycemia in humans are discussed in
depth. A plethora of examples for future gut-based glucose-
lowering approaches involving microbiota, include, among
others, development of probiotic therapies and personalised
nutrition, identification of therapeutic components of
probiotics, targeted delivery of propionate in the right
colon, targeted delivery of metformin in the lower gut,
transplantation of faecal microbiota, and the incorporation
of genetically modified bacteria which express therapeutic
factors into microbiota. All in all, further large randomized
clinical trials are mandatory for the further strengthen of the
very promising evidence-based results of animal models and
their establishment as a standard therapy for T2DM patients
with metabolic profile.
Speaker Biography
Michael Doulberis is a Medical Doctor, Veterinarian as well as a PhD holder. He is
currently working as Resident of internal medicine and has the aspiration to further
focus on gastroenterology. He has a special research interest on investigating the
interactions between immune system and gut microbiota and how the latter can
influence the character and shape the responses of immune system. Moreover, he
has studied how microbial products can beneficially alter the microenviroment of
inflammation and inflammation-associated cancer, as proposed by the so-called
hygiene hypothesis model
.
e:
doulberis@gmail.com